—各奖项申报陆续启动,欢迎关注—随着恒瑞医药、派格生物等医药企业成功登陆港股,今年的港股IPO似有回暖之势。从研发投入看,近几年港股医药公司更是增长了不少。2024年港股医药公司研发费用TOP10公司投入总额达418.28亿元,相比2023年的374.41亿元增长了11.7%,相比2022年的351.02亿元增长了19.16%。制图:医药魔方Invest百济神州以20亿美元的研发投入位居港股乃至...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.